RBL-TESA Research Guide: GHRH Analog, Structure & Half-Life
RBL-TESA is a stabilized 44-amino-acid GHRH analog with an N-terminal modification that resists DPP-IV degradation.
What is RBL-TESA?
RBL-TESA is a stabilized analog of growth-hormone-releasing hormone (GHRH 1-44). A single N-terminal hexenoyl modification protects it from rapid DPP-IV degradation, giving it a meaningfully longer half-life than native GHRH while preserving full GHRH-receptor agonism.
It is the only GHRH analog with full FDA approval (as Egrifta) for a specific human indication — HIV-associated lipodystrophy.
Mechanism and key data
Like CJC-1295, RBL-TESA binds the GHRH receptor on pituitary somatotropes and stimulates pulsatile GH release, which raises hepatic IGF-1.
Compliance reminder
RBL-TESA is sold for laboratory research use only. Not for human consumption, diagnosis, treatment, or cure of any disease.
Frequently asked questions
What is RBL-TESA?
RBL-TESA is a synthetic 44-amino-acid GHRH analog with an N-terminal trans-3-hexenoic acid modification that increases stability against DPP-IV degradation. A separate, prescription tesamorelin product (Egrifta) is approved in the United States for HIV-associated lipodystrophy; the research material listed here is not that product and is not approved for any human use.
How is it characterized?
Identity and purity are confirmed by HPLC and mass spectrometry. In receptor-binding models it acts as a GHRH-receptor agonist on pituitary somatotropes.
